<DOC>
	<DOCNO>NCT02859701</DOCNO>
	<brief_summary>Single-centre , randomise , double blind , placebo control , single ascend dose study . The study comprise 2 part : Part A ( Cohorts 1 2 ) ; Part B ( Cohorts 3 8 ) .</brief_summary>
	<brief_title>Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics AK002 Healthy Participants</brief_title>
	<detailed_description>Participants meet inclusion none exclusion criterion enrol study . Safety tolerability evaluate throughout study . Blood sample PK PD analysis also collect course study . Up approximately 48 participant enrol study . Participants screen -28 day prior dose administration . Participants admit unit Day -1 remain confined clinic completion Day 4 procedure . On Day 1 , participant receive single dose AK002 placebo complete study procedure . Participants return clinic follow Days 7 , 14 , 28 , 56 , 84 112 end study ( EOS ) visit .</detailed_description>
	<criteria>1 . Normal healthy volunteer , age screen 18 65 year , inclusive . 2 . Determined Investigator good health , document medical history , physical examination ( include , limited , evaluation cardiovascular , gastrointestinal , respiratory central nervous system ) , vital sign assessment , clinical laboratory assessment , general observation . 3 . Participants must weigh least 50 kg Body Mass Index ( BMI ) 18 30 kg/m2 Inclusive . 4 . Participants must clinical laboratory value within &lt; 1.5 x upper limit normal ( ULN ) specify test laboratory , unless deem clinically significant Investigator . 5 . Consumed average 3 drink per day within 6 month prior administration study drug ( beer [ 284 mL ] , wine [ 125 mL ] distil spirit [ 25 mL ] ) . 6 . Participants must negative urine drug screen /alcohol breath test screen Day 1 . 7 . Stool sample negative parasite . 8 . Participants must ability willingness attend necessary visit study centre . 9 . Written inform consent sign prior entry study . 10 . Participants must able communicate effectively study site personnel . 11 . Participants use highly effective , double barrier contraception ( male female partner ) study 90 day follow dose AK002 1 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) . 2 . The participant underlying physical psychological medical condition , opinion Investigator , would make unlikely participant complete study . 3 . The participant evidence medical surgical disease condition , opinion Investigator , might compromise haematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , skeletal , central nervous system ; condition may interfere absorption , distribution , metabolism excretion AK002 , would place participant increase risk . 4 . The participant history cancer , except basal cell carcinoma remission least 5 year prior Day 1 5 . Use new drug ( include prescription overthecounter drug herbal supplement ) within 1 week 5 halflives ( whichever longer ) , prior administration study drug . 6 . Use prescription medication neutraceuticals within 30 day randomization . 7 . Use overthe counter medication ( exception paracetamol ) , vitamin supplement , herbal medicine within 7 day randomization . 8 . Participants initiate immunotherapy 90 day Screening visit monthly regimen allergy prevention treatment may consider inclusion , 9 . Use immunosuppressant , oral corticosteroid , angiotensin convert enzyme ( ACE ) inhibitor beta blocker within 2 week 5 halflives ( whichever longer ) , prior Screening . 10 . Any clinically significant laboratory abnormality ECG . 11 . The participant know hypersensitivity component formulation AK002 . 12 . Absolute neutrophil count &lt; 1500/microliter . 13 . Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &gt; 1.5 x ULN unless deem clinically significant Investigator discretion . 14 . The participant history presence alcoholism drug abuse within 2 year prior first study drug administration , unwilling agree abstain alcohol limitation drug throughout study . 15 . The participant use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 3 month prior Checkin ( Day 1 ) . Cotinine urine test positive Screening Checkin ( Day 1 ) . 16 . The participant poor peripheral venous access . 17 . Blood donation significant blood loss ( 500 mL ) within 60 day 18 . Plasma donation within 7 day prior Day 1 . 19 . Administration Investigational Product ( IP ) another trial within 30 day prior first study drug administration ( within 5 half life drug , whichever long ) . 20 . Females pregnant lactate intend become pregnant , , within 90 day participate study ; intend donate ova time period . 21 . Surgery within past three month prior first study drug administration determine PI clinically relevant . 22 . Failure satisfy PI fitness participate reason . 23 . History severe allergic anaphylactic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>